Therefore, inhibition of ghrelin acylation or stimulation of ghrelin deacylation might represent a promising drug target for treatment of obesity, although the reduced absolute AcG levels in obesity don’t suggest this assumption prima facie: If these pharmacologic interventions beneficially changed the AcG/UnG ratio towards lower values, they could have therapeutic effects on treatment of obesity despite the reduced absolute AcG levels. Here, GHRL is linked to obesity due to melanocortin 4 receptor deficiency.